Cardiff Oncology Inc
NASDAQ:CRDF
Market Cap (Intraday) | 93.77M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $2.24 |
50-Day MA | $2.29 |
200-Day MA | $2.73 |
Cardiff Oncology Inc Stock, NASDAQ:CRDF
11055 Flintkote Avenue, Suite B, San Diego, California 92121
United States of America
Phone: +1.858.952.7570
Number of Employees: 32
Description
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.